• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Ustekinumab.优特克单抗
MAbs. 2009 May-Jun;1(3):216-21. doi: 10.4161/mabs.1.3.8593.
2
Ustekinumab for the treatment of psoriatic arthritis.乌司奴单抗治疗银屑病关节炎。
Expert Rev Clin Immunol. 2014 Feb;10(2):189-202. doi: 10.1586/1744666X.2014.878649.
3
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.乌司奴单抗治疗银屑病、银屑病关节炎和克罗恩病的安全性：Ⅱ/Ⅲ期临床开发项目的综合分析。
Drug Saf. 2019 Jun;42(6):751-768. doi: 10.1007/s40264-019-00797-3.
4
Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.优特克单抗：斑块状银屑病和银屑病关节炎治疗的综述
J Drugs Dermatol. 2012 Feb;11(2):160-7.
5
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.优特克单抗治疗克罗恩病：设计、研发及在治疗中的潜在地位
Drug Des Devel Ther. 2016 Nov 11;10:3685-3698. doi: 10.2147/DDDT.S102141. eCollection 2016.
6
Ustekinumab for psoriasis and psoriatic arthritis.优特克单抗用于治疗银屑病和银屑病关节炎。
J Rheumatol Suppl. 2012 Jul;89:86-9. doi: 10.3899/jrheum.120253.
7
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.优特克单抗，一种人白细胞介素12/23单克隆抗体，用于治疗银屑病关节炎：随机、双盲、安慰剂对照、交叉试验。
Lancet. 2009 Feb 21;373(9664):633-40. doi: 10.1016/S0140-6736(09)60140-9. Epub 2009 Feb 11.
8
New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.皮肤科新型白细胞介素-23 通路抑制剂：乌司奴单抗、布罗利尤单抗和司库奇尤单抗。
Am J Clin Dermatol. 2011 Apr 1;12(2):113-25. doi: 10.2165/11538950-000000000-00000.
9
Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.乌司奴单抗：针对免疫介导性疾病中白细胞介素-12/23p40 的经验教训。
Ann N Y Acad Sci. 2009 Dec;1182:97-110. doi: 10.1111/j.1749-6632.2009.05070.x.
10
Spotlight on ustekinumab in moderate to severe plaque psoriasis.聚焦于中重度斑块状银屑病的乌司奴单抗。
Am J Clin Dermatol. 2012 Apr 1;13(2):135-7. doi: 10.2165/11208650-000000000-00000.

引用本文的文献

1
Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy.银屑病管理中的感染风险与疫苗接种：生物治疗的考量
Psoriasis (Auckl). 2025 Apr 11;15:127-144. doi: 10.2147/PTT.S510141. eCollection 2025.
2
Brain interleukins and Alzheimer's disease.脑白介素与阿尔茨海默病。
Metab Brain Dis. 2025 Feb 1;40(2):116. doi: 10.1007/s11011-025-01538-5.
3
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease.在炎症性肠病中，接受优特克单抗治疗的临床缓解者血清嗜酸性粒细胞增多有所改善，而接受阿达木单抗治疗者则未出现此现象。
J Crohns Colitis. 2025 Jan 11;19(1). doi: 10.1093/ecco-jcc/jjaf006.
4
Roles of Cytokines in Alzheimer's Disease.细胞因子在阿尔茨海默病中的作用。
Int J Mol Sci. 2024 May 26;25(11):5803. doi: 10.3390/ijms25115803.
5
Biologics and Biosimilars in Psoriasis.银屑病中的生物制剂和生物类似药
Indian J Dermatol. 2023 May-Jun;68(3):282-295. doi: 10.4103/ijd.ijd_421_23.
6
The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment.白细胞介素-17 在幼年特发性关节炎中的作用：从发病机制到治疗。
Medicina (Kaunas). 2022 Oct 28;58(11):1552. doi: 10.3390/medicina58111552.
7
Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases.药物再利用以改善风湿免疫性炎症性疾病的治疗。
Nat Rev Rheumatol. 2020 Jan;16(1):32-52. doi: 10.1038/s41584-019-0337-0. Epub 2019 Dec 12.
8
Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.用于维持克罗恩病缓解的抗IL-12/23 p40抗体
Cochrane Database Syst Rev. 2019 Dec 12;12(12):CD012804. doi: 10.1002/14651858.CD012804.pub2.
9
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date.司库奇尤单抗及其在斑块状银屑病治疗中的潜力聚焦：迄今的证据
Psoriasis (Auckl). 2018 Nov 13;8:83-92. doi: 10.2147/PTT.S165943. eCollection 2018.
10
Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions.慢性鼻-鼻窦炎中的生物制剂：最新进展及未来方向思考
Am J Rhinol Allergy. 2018 Sep;32(5):412-423. doi: 10.1177/1945892418787132. Epub 2018 Jul 19.

本文引用的文献

1
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?白细胞介素-12/白细胞介素-23抗体疗法为何在多发性硬化症治疗中失败？
Expert Rev Neurother. 2009 Mar;9(3):319-21. doi: 10.1586/14737175.9.3.319.
2
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.优特克单抗，一种人白细胞介素12/23单克隆抗体，用于治疗银屑病关节炎：随机、双盲、安慰剂对照、交叉试验。
Lancet. 2009 Feb 21;373(9664):633-40. doi: 10.1016/S0140-6736(09)60140-9. Epub 2009 Feb 11.
3
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.乌司奴单抗（一种人白细胞介素-12/23单克隆抗体）用于中重度克罗恩病患者的随机试验。
Gastroenterology. 2008 Oct;135(4):1130-41. doi: 10.1053/j.gastro.2008.07.014. Epub 2008 Jul 17.
4
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.复发缓解型多发性硬化症患者皮下重复注射IL12/23 p40中和抗体优特克单抗：一项II期、双盲、安慰剂对照、随机、剂量范围研究。
Lancet Neurol. 2008 Sep;7(9):796-804. doi: 10.1016/S1474-4422(08)70173-X.
5
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).优特克单抗（一种人白细胞介素-12/23单克隆抗体）治疗银屑病患者的疗效和安全性：一项随机、双盲、安慰剂对照试验（PHOENIX 2）的52周结果
Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6.
6
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).优特克单抗（一种人白细胞介素-12/23单克隆抗体）治疗银屑病患者的疗效和安全性：一项随机、双盲、安慰剂对照试验（PHOENIX 1）的76周结果
Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4.
7
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.银屑病和银屑病关节炎管理的护理指南：第2节。银屑病关节炎：概述及以生物制剂为重点的治疗护理指南。
J Am Acad Dermatol. 2008 May;58(5):851-64. doi: 10.1016/j.jaad.2008.02.040.
8
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.银屑病和银屑病关节炎管理的护理指南：第1节。银屑病概述及生物制剂治疗银屑病的护理指南。
J Am Acad Dermatol. 2008 May;58(5):826-50. doi: 10.1016/j.jaad.2008.02.039.
9
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.全人源白细胞介素12/23单克隆抗体ABT-874治疗中度至重度慢性斑块状银屑病的安全性和有效性：一项随机、安慰剂对照的2期试验结果
Arch Dermatol. 2008 Feb;144(2):200-7. doi: 10.1001/archdermatol.2007.63.
10
Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275.CNTO 1275对CLA、IL-12R、CD40L和IL-2Rα表达的调节作用以及对IL-12和IL-23诱导的细胞因子分泌的抑制作用。
Cell Immunol. 2007 May;247(1):1-11. doi: 10.1016/j.cellimm.2007.06.006. Epub 2007 Aug 29.

优特克单抗

Ustekinumab.

作者信息

Cingoz Oya

机构信息

Department of Molecular Biology and Microbiology; Tufts University School of Medicine; Boston, MA 02111, USA.

出版信息

MAbs. 2009 May-Jun;1(3):216-21. doi: 10.4161/mabs.1.3.8593.

DOI:10.4161/mabs.1.3.8593
PMID:20069753
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2726595/
Abstract

Ustekinumab is an anti-IL12/23 IgG1 kappa human monoclonal antibody currently undergoing US Food and Drug Administration review for use as a psoriasis treatment. The candidate has also been evaluated in Phase 2 studies as a treatment for psoriatic arthritis, Crohn disease and multiple sclerosis.In large clinical trials, ustekinumab has proven effective for treating moderate to severe plaque psoriasis. Although long-term follow-up studies are needed to address safety concerns, the hopes are high for psoriasis treatment. Ustekinumab has recently been approved for marketing in Canada and Europe.

摘要

优特克单抗是一种抗白细胞介素12/23的IgG1κ人源单克隆抗体，目前正在接受美国食品药品监督管理局的审查，用于治疗银屑病。该候选药物也已在2期研究中作为银屑病关节炎、克罗恩病和多发性硬化症的治疗方法进行了评估。在大型临床试验中，优特克单抗已被证明对治疗中度至重度斑块状银屑病有效。尽管需要长期随访研究来解决安全问题，但治疗银屑病的前景十分乐观。优特克单抗最近已在加拿大和欧洲获批上市。